Vaidya Sane Ayurved Laboratories Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Revenue growth steady, not accelerating: FY26 revenue grew 18.89% YoY, driven by higher patient engagement and wellness product sales, but the pace fell short of earlier 30% ambitions and management now calls 18–20% "healthy."
• Strategic pivot to higher-value care: A conscious shift from preventive plans (₹10,000–₹13,000) to disease reversal programs (₹50,000–₹60,000) is improving realization per patient and doctor utilization, though care plan conversions in the higher bracket dipped year on year.
• Franchise engine stalled, hospital beds are the new growth lever: Franchise count has been flat for three years while marketing was "deranged"; expansion now hinges on filling existing clinics first and adding 140–150 hospital beds by March 2027.
• Margins under pressure from call centre spend: H2 EBITDA declined as a new call centre added ₹50–60 lakh per month; management targets a climb from 15% toward 20% EBITDA in FY27, calling it "doable" if manpower and COGS stay controlled.
• What to watch next quarter: Whether the Dubai franchise opens on schedule, the CGHS portal goes live for Khopoli, and any concrete decision on the main board migration, all flagged for the "next couple of months."

Growth Drivers & Strategic Shift

• Disease reversal over prevention: The business historically relied on preventive healthcare with lower annual ticket sizes. The deliberate shift to specialized disease reversal programs for cardiac disorders, diabetes, hypertension and obesity lifts average realization per patient and better leverages doctors' expertise.
• Wellness product sales: Robust growth in product sales contributed to the 18.89% YoY revenue increase, alongside sustained patient additions and growing acceptance of Ayurveda healthcare solutions.
• Digital brand building: Social media following has grown from thousands to roughly 1.5 lakh followers on Instagram and YouTube, and about one lakh on YouTube, signalling rising brand awareness on digital channels.
• Madhavprash retail experiment: The company's Chavanprash for heart ailments is now on quick commerce and all commercial sites; a small trial with generic retail outlets has begun and the first trial should conclude in the next three months, after which wider retail expansion will be planned.

Dr. Rohit Madhav Sane: "This transition is not only improving our average realization per patient, but also allowing us to better utilize our doctors' expertise, strengthen patient outcomes and improve profitability across the network."

Franchise & Clinic Network

• Three-year stall in franchise growth: Franchise count has not increased in the last three years. Management attributes this to marketing being "deranged to a certain extent" and a deliberate choice to nourish existing clinics with more new patients before expanding into newer geographies.
• Clinic count reduction: Total clinics reduced from roughly 335 to 320 after a small experiment with non-medical franchise owners, where the owner would hire a doctor, did not work as expected and those clinics were discontinued.
• Care plan conversion decline: Higher-ticket care plan conversions (₹45,000 to ₹60,000 range) fell from 33,800 in FY25 to 28,000–29,000 in FY26. Management notes that diet care plans, roughly 37,000 in number, are excluded from this figure because the ticket size is too small to track.
• Patient inflow: Monthly patient inflow stands at about 11,000 over the last two months, which management considers a good number given the first three to four months of the year are typically slower.
• Franchise expansion restart: The company expects to add approximately 30 to 40 franchise clinics in the next year or so, contingent on marketing increasing and new patient footfall rising at existing clinics first.

Dr. Rohit Madhav Sane: "The reason is that we have stopped because I want to nourish the existing franchise clinics with more number of new patients. Once that happens, then we will be growing with the number of franchise clinics in the newer geography."

Hospital Expansion & Bed Capacity

• Bed capacity target: The company plans to increase hospital bed capacity to 250–300 over the next 12 to 15 months through expansions in Khopoli and Nagpur, plus scaling up the Vadodara hospital.
• Khopoli construction timeline: The third slab of seven is complete; the target is to finish the seventh slab before the rains begin in the next 2–2.5 months, with 150 constructed hospital beds ready by March 2027. Post-monsoon this year, at least 15–20 extra beds will be added on the first floor.
• Nagpur and Baroda: Nagpur is waiting for government permissions before setup begins. Baroda will add a top floor with roughly 75 beds once current accommodation reaches about 60% occupancy.
• Revenue mix ambition: Management wants to evolve from the current clinic-heavy structure toward a 50:50 mix between clinics and hospitals over the medium term, with hospital revenue of ₹100–125 crore targeted by FY28.
• Blended hospital ARPU: Approximately ₹70,000, with Khopoli hospital alone expected to contribute about 50% of total hospital revenue at roughly 150 beds.

Acquisitions & Partnerships

• Parasnath Health Care acquisition: A chain of roughly 70 franchise clinics focused on joint pain treatment through Ayurveda, operating for 10–12 years. Acquired for ₹6 crore equity value with a turnover of ₹14 crore and EBITDA of roughly ₹1.1 crore, leaving significant room for margin improvement. Not yet consolidated in FY26 results; will become a subsidiary in the current financial year.
• Cross-referral strategy: Parasnath joint pain patients with heart disease will be referred to Madhavbaug hospitals and clinics, while Madhavbaug patients with joint pain will be referred to Parasnath clinics, creating an integrated care loop.
• Urja Neuro Care investment: A strategic diversification into neurological disorders including Parkinson's, paralysis rehabilitation and Alzheimer's care through Ayurvedic approaches.
• International expansion via Malaysia: A partnership with Maxura Healthcare marks the beginning of the global journey, using an asset-light model that can serve as a template for future international growth and validates the scalability of evidence-based Ayurvedic disease reversal protocols.
• Infertility clinic discussions: Talks with existing doctors practicing infertility are at an advanced stage; management expects to speak about it in the coming couple of months.

Dr. Rohit Madhav Sane: "we will be integrating these clinics treatments with our existing hospitals so that the cross referral in between these clinics to the hospital as well as Madhavbaug clinics for all those joint patients who have heart diseases would be referred to Madhavbaug as well as Madhavbaug patients who have joint pains will be referred to these clinics."

Margins & Cost Structure

• FY26 EBITDA: Increased 7.63% driven by better cost control, especially in employee and raw material expenses, along with an improved product mix.
• H2 EBITDA decline: The primary reason was the new call centre, which added an extra expense of ₹50–60 lakh per month.
• Material cost control: Material cost stayed at 18% of revenue (₹18 crore) despite revenue rising from ₹90 crore to ₹107 crore. When an analyst questioned whether this might indicate customers are not getting their money's worth, management did not directly address the concern, stating only "that is kept in control."
• Other expenses classification: An analyst noted other expenses exceed 50% of total expenses and suggested proper classification should bring them to around 10%. Management responded that excluding marketing expense would bring it to 10%, but did not provide a detailed breakdown, saying "details are not handy with me."
• FY27 cost structure: Management expects the cost structure to land somewhere between H1 and H2 levels, with the decisive factor being marketing cost to acquire new patients.

Dr. Rohit Madhav Sane: "As I said, we will be growing from 15% towards 20% in this year itself. And that is doable, keeping the manpower expense in control, as well as the COGS is already well in control."

Revenue Model & Patient Economics

• Enterprise vs company revenue: When the total enterprise grows by roughly ₹100, only about ₹40 flows into company books, reflecting a 40% capture rate. This explains why company-level growth appears lower than enterprise-level growth.
• FY27 revenue build: If two lakh new patients come in, enterprise revenue for clinics would be roughly ₹280 crore, of which 40% (₹120–130 crore) would come to Vaidya Sane, plus roughly ₹50 crore from hospitals, totalling approximately ₹180 crore.
• Marketing spend: Budgeted at ₹40–45 crore per year for FY27 to acquire roughly two lakh new patients at a cost of approximately ₹2,000 per patient.
• ARPU assumption: A marginal 5–10% increase is expected but not yet factored into projections.
• Inventory increase: March sees clinics more activated, so more products are ordered in the depot, causing a seasonal inventory build.

Guidance & Commitments

Key Metrics